Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses MRK in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named MRK in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Robert Davis | $1,645,302 | $0 | $12,102,838 | $3,380,004 | $2,326,500 | $685,143 | $658,058 | $20,797,845 |
| Chairman, Chief Executive Officer and President | ||||||||
| Dean Li | 1,460,000 | 0 | 4,296,864 | 1,199,991 | 1,368,640 | 398,839 | 168,547 | 8,892,881 |
| Executive Vice President and President, Merck Research Laboratories | ||||||||
| Caroline Litchfield | 1,173,214 | 0 | 3,580,681 | 1,000,008 | 1,099,800 | 532,764 | 127,618 | 7,514,085 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Jennifer Zachary | 1,062,217 | 0 | 2,685,571 | 750,002 | 995,749 | 254,317 | 112,722 | 5,860,578 |
| Executive Vice President and General Counsel | ||||||||
| Sanat Chattopadhyay | 982,170 | 0 | 2,363,261 | 660,004 | 920,710 | 291,064 | 191,199 | 5,408,408 |
| Executive Vice President and President, Merck Manufacturing Division | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Robert Davis | $20,797,845 | $23,186,064 | $20,273,287 | −2,388,219 |
| Dean Li | 8,892,881 | 10,086,332 | 9,779,414 | −1,193,451 |
| Caroline Litchfield | 7,514,085 | 7,507,778 | 8,300,385 | +6,307 |
| Jennifer Zachary | 5,860,578 | — | — | — |
| Sanat Chattopadhyay | 5,408,408 | — | 6,240,360 | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dividend-equivalent accruals | 2026-04-29 | — | 6,129 | — | — | 4 insiders, 5 accrual rows | ||
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-04-29 | D | 159 | 111 | 17,641 | Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-04-29 | A | 464 | 111 | 51,481 | Common | Form 4 ↗ |
| Jennifer Zachary | EVP, General Counsel | 2026-04-29 | D | 1,454 | 110 | 159,984 | Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-04-29 | D | 715 | 110 | 78,671 | Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-04-29 | D | 5,143 | 111 | 570,616 | Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-04-29 | D | 11,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dean Li | Executive VP & President, MRL | 2026-04-29 | D | 4,722 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dean Li | Executive VP & President, MRL | 2026-04-29 | D | 2,326 | 110 | 255,930 | Common | Form 4 ↗ |
| Dean Li | Executive VP & President, MRL | 2026-04-29 | A | 4,722 | 110 | 519,562 | Common | Form 4 ↗ |
| Robert M. Davis | Director | 2026-04-29 | D | 6,551 | 110 | 720,807 | Common | Form 4 ↗ |
| David Michael Williams | EVP,Chief Info&Digital Officer | 2026-04-29 | D | 679 | 110 | 74,710 | Common | Form 4 ↗ |
| Jennifer Zachary | EVP, General Counsel | 2026-04-29 | A | 2,951 | 110 | 324,699 | Common | Form 4 ↗ |
| Sanat Chattopadhyay | Exe V-P & Pres. MMD | 2026-04-29 | D | 1,130 | 110 | 124,334 | Common | Form 4 ↗ |
| Sanat Chattopadhyay | Exe V-P & Pres. MMD | 2026-04-29 | D | 2,597 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Michael Williams | EVP,Chief Info&Digital Officer | 2026-04-29 | A | 1,377 | 110 | 151,511 | Common | Form 4 ↗ |
| Jennifer Zachary | EVP, General Counsel | 2026-04-29 | D | 2,951 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-04-29 | A | 11,350 | 111 | 1,259,283 | Common | Form 4 ↗ |
| Caroline Litchfield | EVP & CFO | 2026-04-29 | D | 3,935 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert M. Davis | Director | 2026-04-29 | D | 13,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 2026-04-29 | D | 679 | 110 | 74,710 | Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-04-29 | A | 2,085 | 110 | 229,413 | Common | Form 4 ↗ |
| Caroline Litchfield | EVP & CFO | 2026-04-29 | D | 1,938 | 110 | 213,238 | Common | Form 4 ↗ |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 2026-04-29 | A | 1,377 | 110 | 151,511 | Common | Form 4 ↗ |
| Chirfi Guindo | EVP, Access, Policy & Comms | 2026-04-29 | A | 1,967 | 110 | 216,429 | Common | Form 4 ↗ |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 2026-04-29 | A | 2,518 | 110 | 277,056 | Common | Form 4 ↗ |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 2026-04-29 | D | 1,241 | 110 | 136,547 | Common | Form 4 ↗ |
| Robert M. Davis | Director | 2026-04-29 | A | 13,300 | 110 | 1,463,399 | Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-04-29 | A | 944 | 110 | 103,868 | Common | Form 4 ↗ |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 2026-04-29 | D | 2,518 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chirfi Guindo | EVP, Access, Policy & Comms | 2026-04-29 | D | 969 | 110 | 106,619 | Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-04-29 | D | 2,085 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Caroline Litchfield | EVP & CFO | 2026-04-29 | A | 3,935 | 110 | 432,968 | Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-04-29 | D | 324 | 110 | 35,650 | Common | Form 4 ↗ |
| Sanat Chattopadhyay | Exe V-P & Pres. MMD | 2026-04-29 | A | 2,597 | 110 | 285,748 | Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-05-02 | A | 383 | 112 | 42,957 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-02 | — | 935 | — | — | 2 insiders, 2 accrual rows | ||
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-05-02 | D | 132 | 112 | 14,805 | Common | Form 4 ↗ |
| David R. Maraldo | EVP & Pres. MMD | 2026-05-02 | D | 159 | 112 | 17,833 | Common | Form 4 ↗ |
| David R. Maraldo | EVP & Pres. MMD | 2026-05-02 | A | 552 | 112 | 61,912 | Common | Form 4 ↗ |
| Chirfi Guindo | EVP, Access, Policy & Comms | 2026-05-05 | A | 19,402 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chirfi Guindo | EVP, Access, Policy & Comms | 2026-05-05 | A | 6,628 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Zachary | EVP, General Counsel | 2026-05-05 | A | 12,064 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David R. Maraldo | EVP & Pres. MMD | 2026-05-05 | A | 7,424 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 2026-05-05 | A | 10,605 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dean Li | Executive VP & President, MRL | 2026-05-05 | A | 58,207 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-05-05 | A | 23,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert M. Davis | Director | 2026-05-05 | A | 47,724 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-05-05 | A | 5,045 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Zachary | EVP, General Counsel | 2026-05-05 | A | 35,312 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Michael Williams | EVP,Chief Info&Digital Officer | 2026-05-05 | A | 13,582 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Caroline Litchfield | EVP & CFO | 2026-05-05 | A | 15,908 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Caroline Litchfield | EVP & CFO | 2026-05-05 | A | 46,566 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dean Li | Executive VP & President, MRL | 2026-05-05 | A | 19,885 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-05-05 | A | 7,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 2026-05-05 | A | 11,931 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 2026-05-05 | A | 34,924 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert M. Davis | Director | 2026-05-05 | A | 139,697 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Foard | EVP, Specialty, Pharma, & ID | 2026-05-05 | A | 10,605 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Foard | EVP, Specialty, Pharma, & ID | 2026-05-05 | A | 35,351 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Foard | EVP, Specialty, Pharma, & ID | 2026-05-05 | A | 31,044 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David R. Maraldo | EVP & Pres. MMD | 2026-05-05 | A | 21,731 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 2026-05-05 | A | 31,044 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-05-05 | A | 2,298 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Michael Williams | EVP,Chief Info&Digital Officer | 2026-05-05 | A | 4,640 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Douglas M. Baker Jr | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Thomas H. Glocer | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Paul Rothman | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Christine E. Seidman | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Surendralal L. Karsanbhai | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Mayo | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Patricia F. Russo | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Pamela J. Craig | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Inge G. Thulin | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Kathy J. Warden | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Mary Ellen Coe | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Risa J. Lavizzo-Mourey | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Mary Ellen Coe | Director | 2026-06-30 | A | 233.46 | 129 | 30,000 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-30 | — | 63 | — | ~8,125 | 1 insider, 1 accrual row | ||
| Surendralal L. Karsanbhai | Director | 2026-06-30 | A | 126.46 | 129 | 16,250 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-04-29 | D | 464 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-04-29 | D | 159 | 111 | 17,641 | Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-04-29 | A | 464 | 111 | 51,481 | Common | Form 4 ↗ |
| Jennifer Zachary | EVP, General Counsel | 2026-04-29 | D | 1,454 | 110 | 159,984 | Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-04-29 | D | 715 | 110 | 78,671 | Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-04-29 | D | 5,143 | 111 | 570,616 | Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-04-29 | D | 11,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dean Li | Executive VP & President, MRL | 2026-04-29 | D | 4,722 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dean Li | Executive VP & President, MRL | 2026-04-29 | D | 2,326 | 110 | 255,930 | Common | Form 4 ↗ |
| Dean Li | Executive VP & President, MRL | 2026-04-29 | A | 4,722 | 110 | 519,562 | Common | Form 4 ↗ |
| Robert M. Davis | Director | 2026-04-29 | D | 6,551 | 110 | 720,807 | Common | Form 4 ↗ |
| David Michael Williams | EVP,Chief Info&Digital Officer | 2026-04-29 | D | 679 | 110 | 74,710 | Common | Form 4 ↗ |
| Jennifer Zachary | EVP, General Counsel | 2026-04-29 | A | 2,951 | 110 | 324,699 | Common | Form 4 ↗ |
| Chirfi Guindo | EVP, Access, Policy & Comms | 2026-04-29 | D | 1,967 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanat Chattopadhyay | Exe V-P & Pres. MMD | 2026-04-29 | D | 1,130 | 110 | 124,334 | Common | Form 4 ↗ |
| Sanat Chattopadhyay | Exe V-P & Pres. MMD | 2026-04-29 | D | 2,597 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Michael Williams | EVP,Chief Info&Digital Officer | 2026-04-29 | A | 1,377 | 110 | 151,511 | Common | Form 4 ↗ |
| David Michael Williams | EVP,Chief Info&Digital Officer | 2026-04-29 | D | 1,377 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-04-29 | D | 944 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Zachary | EVP, General Counsel | 2026-04-29 | D | 2,951 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-04-29 | A | 11,350 | 111 | 1,259,283 | Common | Form 4 ↗ |
| Caroline Litchfield | EVP & CFO | 2026-04-29 | D | 3,935 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert M. Davis | Director | 2026-04-29 | D | 13,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 2026-04-29 | D | 1,377 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 2026-04-29 | D | 679 | 110 | 74,710 | Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-04-29 | A | 2,085 | 110 | 229,413 | Common | Form 4 ↗ |
| Caroline Litchfield | EVP & CFO | 2026-04-29 | D | 1,938 | 110 | 213,238 | Common | Form 4 ↗ |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 2026-04-29 | A | 1,377 | 110 | 151,511 | Common | Form 4 ↗ |
| Chirfi Guindo | EVP, Access, Policy & Comms | 2026-04-29 | A | 1,967 | 110 | 216,429 | Common | Form 4 ↗ |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 2026-04-29 | A | 2,518 | 110 | 277,056 | Common | Form 4 ↗ |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 2026-04-29 | D | 1,241 | 110 | 136,547 | Common | Form 4 ↗ |
| Robert M. Davis | Director | 2026-04-29 | A | 13,300 | 110 | 1,463,399 | Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-04-29 | A | 944 | 110 | 103,868 | Common | Form 4 ↗ |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 2026-04-29 | D | 2,518 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chirfi Guindo | EVP, Access, Policy & Comms | 2026-04-29 | D | 969 | 110 | 106,619 | Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-04-29 | D | 2,085 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Caroline Litchfield | EVP & CFO | 2026-04-29 | A | 3,935 | 110 | 432,968 | Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-04-29 | D | 324 | 110 | 35,650 | Common | Form 4 ↗ |
| Sanat Chattopadhyay | Exe V-P & Pres. MMD | 2026-04-29 | A | 2,597 | 110 | 285,748 | Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-05-02 | A | 383 | 112 | 42,957 | Common | Form 4 ↗ |
| David R. Maraldo | EVP & Pres. MMD | 2026-05-02 | D | 552 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-05-02 | D | 383 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-05-02 | D | 132 | 112 | 14,805 | Common | Form 4 ↗ |
| David R. Maraldo | EVP & Pres. MMD | 2026-05-02 | D | 159 | 112 | 17,833 | Common | Form 4 ↗ |
| David R. Maraldo | EVP & Pres. MMD | 2026-05-02 | A | 552 | 112 | 61,912 | Common | Form 4 ↗ |
| Chirfi Guindo | EVP, Access, Policy & Comms | 2026-05-05 | A | 19,402 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chirfi Guindo | EVP, Access, Policy & Comms | 2026-05-05 | A | 6,628 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Zachary | EVP, General Counsel | 2026-05-05 | A | 12,064 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David R. Maraldo | EVP & Pres. MMD | 2026-05-05 | A | 7,424 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 2026-05-05 | A | 10,605 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dean Li | Executive VP & President, MRL | 2026-05-05 | A | 58,207 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-05-05 | A | 23,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert M. Davis | Director | 2026-05-05 | A | 47,724 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-05-05 | A | 5,045 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Zachary | EVP, General Counsel | 2026-05-05 | A | 35,312 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Michael Williams | EVP,Chief Info&Digital Officer | 2026-05-05 | A | 13,582 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Caroline Litchfield | EVP & CFO | 2026-05-05 | A | 15,908 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Caroline Litchfield | EVP & CFO | 2026-05-05 | A | 46,566 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dean Li | Executive VP & President, MRL | 2026-05-05 | A | 19,885 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Betty D. Larson | EVP, Chief HR Officer | 2026-05-05 | A | 7,954 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 2026-05-05 | A | 11,931 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 2026-05-05 | A | 34,924 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert M. Davis | Director | 2026-05-05 | A | 139,697 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Foard | EVP, Specialty, Pharma, & ID | 2026-05-05 | A | 10,605 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Foard | EVP, Specialty, Pharma, & ID | 2026-05-05 | A | 35,351 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Foard | EVP, Specialty, Pharma, & ID | 2026-05-05 | A | 31,044 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David R. Maraldo | EVP & Pres. MMD | 2026-05-05 | A | 21,731 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 2026-05-05 | A | 31,044 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dalton E. Smart III | SVP Fin. - Global Controller | 2026-05-05 | A | 2,298 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Michael Williams | EVP,Chief Info&Digital Officer | 2026-05-05 | A | 4,640 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Douglas M. Baker Jr | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Thomas H. Glocer | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Paul Rothman | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Christine E. Seidman | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Surendralal L. Karsanbhai | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Mayo | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Patricia F. Russo | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Pamela J. Craig | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Inge G. Thulin | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Kathy J. Warden | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Mary Ellen Coe | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Risa J. Lavizzo-Mourey | Director | 2026-05-29 | A | 1,853.1 | 119 | 220,000 | Derivative, Class A Common | Form 4 ↗ |
| Mary Ellen Coe | Director | 2026-06-30 | A | 233.46 | 129 | 30,000 | Derivative, Class A Common | Form 4 ↗ |
| Christine E. Seidman | Director | 2026-06-30 | A | 63.23 | 129 | 8,125 | Derivative, Class A Common | Form 4 ↗ |
| Surendralal L. Karsanbhai | Director | 2026-06-30 | A | 126.46 | 129 | 16,250 | Derivative, Class A Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Dean Li | OPTION | 2025-04-29 | — | — | 64,481 | — | $1,199,991 |
| Robert Davis | PSU | 2025-03-31 | — | 112,968 | — | 225,936 | 8,722,824 |
| Caroline Litchfield | OPTION | 2025-04-29 | — | — | 53,735 | — | 1,000,008 |
| Dean Li | PSU | 2025-03-31 | — | 40,107 | — | 80,214 | 3,096,862 |
| Caroline Litchfield | RSU | 2025-04-29 | — | — | 11,805 | — | 1,000,002 |
| Caroline Litchfield | PSU | 2025-03-31 | — | 33,422 | — | 66,844 | 2,580,680 |
| Robert Davis | RSU | 2025-04-29 | — | — | 39,901 | — | 3,380,014 |
| Dean Li | RSU | 2025-04-29 | — | — | 14,166 | — | 1,200,002 |
| Robert Davis | OPTION | 2025-04-29 | — | — | 181,623 | — | 3,380,004 |
| Jennifer Zachary | RSU | 2025-04-29 | — | — | 8,854 | — | 750,022 |
| Sanat Chattopadhyay | PSU | 2025-03-31 | — | 22,059 | — | 44,118 | 1,703,286 |
| Jennifer Zachary | PSU | 2025-03-31 | — | 25,067 | — | 50,134 | 1,935,548 |
| Jennifer Zachary | OPTION | 2025-04-29 | — | — | 40,301 | — | 750,002 |
| Sanat Chattopadhyay | RSU | 2025-04-29 | — | — | 7,791 | — | 659,976 |
| Sanat Chattopadhyay | OPTION | 2025-04-29 | — | — | 35,465 | — | 660,004 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Dean Li | $1,200,002 | $3,096,862 | $1,199,991 | 56.3% |
| Robert Davis | 3,380,014 | 8,722,824 | 3,380,004 | 56.3% |
| Caroline Litchfield | 1,000,002 | 2,580,680 | 1,000,008 | 56.3% |
| Jennifer Zachary | 750,022 | 1,935,548 | 750,002 | 56.3% |
| Sanat Chattopadhyay | 659,976 | 1,703,286 | 660,004 | 56.3% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Sanat Chattopadhyay | PSU | 44,118 | — | $4,643,861 |
| Dean Li | Option | 21,014 | 75.36 | — |
| Sanat Chattopadhyay | Option | 35,465 | 84.71 | — |
| Caroline Litchfield | RSU | 11,805 | — | 1,242,594 |
| Dean Li | Option | 15,087 | 56.04 | — |
| Sanat Chattopadhyay | RSU | 7,791 | — | 820,081 |
| Robert Davis | Option | 62,242 | 117.89 | — |
| Jennifer Zachary | Option | 13,832 | 117.89 | — |
| Sanat Chattopadhyay | Option | 25,782 | 129.22 | — |
| Jennifer Zachary | PSU | 31,830 | — | 3,350,426 |
| Dean Li | Option | 64,481 | 84.71 | — |
| Robert Davis | RSU | 39,901 | — | 4,199,979 |
| Robert Davis | PSU | 164,456 | — | 17,310,639 |
| Jennifer Zachary | RSU | 8,854 | — | 931,972 |
| Jennifer Zachary | Option | 40,301 | 84.71 | — |
| Sanat Chattopadhyay | Option | 66,913 | 77.62 | — |
| Caroline Litchfield | PSU | 45,092 | — | 4,746,384 |
| Caroline Litchfield | Option | 33,204 | 129.22 | — |
| Caroline Litchfield | PSU | 66,844 | — | 7,035,999 |
| Dean Li | PSU | 59,416 | — | 6,254,128 |
| Sanat Chattopadhyay | Option | 87,170 | 75.36 | — |
| Sanat Chattopadhyay | PSU | 35,014 | — | 3,685,574 |
| Jennifer Zachary | Option | 56,792 | 73.73 | — |
| Sanat Chattopadhyay | Option | 15,215 | 117.89 | — |
| Jennifer Zachary | Option | 25,946 | 75.36 | — |
| Caroline Litchfield | Option | 20,313 | 75.36 | — |
| Caroline Litchfield | Option | 17,455 | 77.62 | — |
| Dean Li | Option | 3,891 | 75.36 | — |
| Caroline Litchfield | Option | 19,595 | 117.89 | — |
| Robert Davis | Option | 121,094 | 129.22 | — |
| Dean Li | Option | 43,750 | 129.22 | — |
| Jennifer Zachary | Option | 23,438 | 129.22 | — |
| Robert Davis | Option | 181,623 | 84.71 | — |
| Robert Davis | Option | 228,155 | 87.1 | — |
| Robert Davis | Option | 116,370 | 77.62 | — |
| Robert Davis | Option | 96,760 | 73.73 | — |
| Robert Davis | Option | 83,020 | 75.36 | — |
| Caroline Litchfield | Option | 41,997 | 53.06 | — |
| Sanat Chattopadhyay | Option | 58,252 | 87.1 | — |
| Dean Li | Option | 75,728 | 87.1 | — |
| Caroline Litchfield | Option | 53,735 | 84.71 | — |
| Caroline Litchfield | Option | 26,465 | 62.07 | — |
| Caroline Litchfield | Option | 22,630 | 56.04 | — |
| Dean Li | Option | 17,455 | 77.62 | — |
| Robert Davis | PSU | 225,936 | — | 23,782,023 |
| Dean Li | PSU | 80,214 | — | 8,443,326 |
| Jennifer Zachary | PSU | 50,134 | — | 5,277,105 |
| Dean Li | Option | 94,654 | 73.73 | — |
| Sanat Chattopadhyay | Option | 88,343 | 73.73 | — |
| Caroline Litchfield | Option | 69,413 | 73.73 | — |
| Caroline Litchfield | Option | 53,398 | 87.1 | — |
| Jennifer Zachary | Option | 38,835 | 87.1 | — |
| Dean Li | RSU | 14,166 | — | 1,491,113 |
| Dean Li | Option | 25,819 | 117.89 | — |
Our overarching strategy is to position executive compensation competitively relative to the market for comparable roles. In evaluating target Total Direct Compensation (TDC), the C&MD Committee considers the median level of compensation as a reference point.
| CEO STI target (% of salary) | 150% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-26 | 1,730,192,132 | 109,310,633 | 18,017,635 | 94.06% | Passed |
| 2025 | 2025-05-27 | 1,673,231,538 | 156,312,968 | 10,607,107 | 91.46% | Passed |
| 2024 | 2024-05-28 | 1,696,772,487 | 117,948,443 | 9,862,230 | 93.5% | Passed |
| 2023 | 2023-05-23 | 1,697,425,819 | 161,718,633 | 10,693,408 | 91.3% | Passed |
| 2022 | 2022-05-24 | 1,638,611,142 | 144,654,654 | 8,939,006 | 91.89% | Passed |
| 2021 | 2021-05-25 | 1,619,442,173 | 156,048,261 | 24,424,849 | 91.21% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-26 | 94.06%a |
| 2025 | 2025-05-27 | 91.46%b |
| 2024 | 2024-05-28 | 93.5%c |
a. Approved under the standard stated in the filing — “Do not count for all six proposals (no effect)”.
b. Approved under the standard stated in the filing — “ation Broker discretionary voting allowed? Votes required for approval Abstentions and Broker Non-Votes Proposal 1 Election of Directors Page 32 FOR each Nominee No Majority of votes cast Do not count for all seven proposals (no effect) Proposal 2 Non-binding Advisory Vote to Approve the Compensation of our Named Executive Officers (Say-on-Pay) Page 42 FOR No Majority of votes cast Proposal 3 Ratification of Appointment of Independent Registered Public Accounting Firm for 2025 Page 84 FOR Yes Majority of votes cast Proposals 4, 5, 6, and 7 Shareholder Proposals Pages 87 - 93 AGAINST No Majority of votes cast Why did I receive this Proxy Statement? The Board of Directors is soliciting your proxy entions and Broker Non-Votes Proposal 1 Election of Directors Page 32 FOR each Nominee No Majority of votes cast Do not count for all seven proposals (no effect) Proposal 2 Non-binding Advisory Vote to Approve the Compensation of our Named Executive Officers (Say-on-Pay) Page 42 FOR No Majority of votes cast Proposal 3 Ratification of Appointment of Independent Registered Public Accounting Firm for 2025 Page 84 FOR Yes Majority of votes cast Proposals 4, 5, 6, and 7 Shareholder Proposals Pages 87 - 93 AGAINST No Majority of votes cast Why did I receive this Proxy Statement? The Board of Directors is soliciting your proxy uested report.”.
c. Approved under the standard stated in the filing — “ndation Broker discretionary voting allowed? Votes required for approval Abstentions and Broker Non-Votes Proposal 1 Election of Directors Page 35 FOR each Nominee No Majority of votes cast Do not count for all six proposals (no effect) Proposal 2 Non-binding Advisory Vote to Approve the Compensation of our Named Executive Officers (Say-on-Pay) Page 44 FOR No Majority of votes cast Proposal 3 Ratification of Appointment of Independent Registered Public Accounting Firm for 2024 Page 88 FOR Yes Majority of votes cast Proposals 4, 5, and 6 Shareholder Proposals Pages 91 -96 AGAINST No Majority of votes cast Why did I receive this Proxy Statement? The Board of Directors is soliciting your proxy to v stentions and Broker Non-Votes Proposal 1 Election of Directors Page 35 FOR each Nominee No Majority of votes cast Do not count for all six proposals (no effect) Proposal 2 Non-binding Advisory Vote to Approve the Compensation of our Named Executive Officers (Say-on-Pay) Page 44 FOR No Majority of votes cast Proposal 3 Ratification of Appointment of Independent Registered Public Accounting Firm for 2024 Page 88 FOR Yes Majority of votes cast Proposals 4, 5, and 6 Shareholder Proposals Pages 91 -96 AGAINST No Majority of votes cast Why did I receive this Proxy Statement? The Board of Directors is soliciting your proxy to v eak Up culture.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 191 : 1 |
|---|---|
| CEO total compensation | $20,797,845 |
| Median employee compensation | $108,614 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Thomas H. GlocerIndependent · Lead Independent Director · Governance (Chair) · Compensation and Management Development | $195,000 | — | — | $0 | $220,000 | $415,000 |
| Pamela J. CraigIndependent · Audit (Chair) · Governance | 155,000 | — | — | 0 | 250,000 | 405,000 |
| Surendralal L. KarsanbhaiIndependent · Audit · Governance · Newly elected | 130,000 | — | — | 0 | 275,000 | 405,000 |
| Paul B. Rothman, M.DIndependent · Audit · Research (Chair) | 155,000 | — | — | 0 | 250,000 | 405,000 |
| Christine E. Seidman, M.DIndependent · Audit · Research | 130,000 | — | — | 0 | 255,000 | 385,000 |
| Patricia F. RussoIndependent · Compensation and Management Development (Chair) · Governance | 145,000 | — | — | 0 | 220,000 | 365,000 |
| Douglas M. Baker JrIndependent · Audit · Research | 130,000 | 220,000 | 0 | — | 0 | 350,000 |
| Stephen L. Mayo, Ph.DIndependent · Audit · Research (Chair) | 130,000 | — | — | 0 | 220,000 | 350,000 |
| Risa J. Lavizzo-Mourey, M.DIndependent · Compensation and Management Development | 120,000 | — | — | 0 | 220,000 | 340,000 |
| Kathy J. WardenIndependent · Compensation and Management Development · Governance | 120,000 | — | — | 0 | 220,000 | 340,000 |
| Inge G. ThulinIndependent · Compensation and Management Development · Governance | 120,000 | — | — | 0 | 220,000 | 340,000 |
| Mary Ellen CoeIndependent · Compensation and Management Development · Research | 120,000 | — | — | 0 | 220,000 | 340,000 |
| Robert M. DavisEmployee director · Board Chair | 0 | — | — | — | 0 | 0 |
| Annual cash retainer | $120,000 |
|---|---|
| Annual equity retainer | $220,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 35,000 / 25,000 / 25,000 |
| Stock ownership guideline | 5x annual cash retainer |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,650,000 |
| Equity awards (grant-date value) | $220,000 |
| All other compensation | $2,570,000 |
| Total cost of the board | $4,440,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Merck & Co., Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Merck & Co., Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Microsoft | 2025 | Satya Nadella | $2,500,000 | $84,245,496 | $0 | $9,555,000 | $96,496,790 |
| 2 | Apple | 2025 | Tim Cook | 3,000,000 | 57,535,293 | 0 | 12,000,000 | 74,294,811 |
| 3 | UnitedHealth Group | 2025 | Stephen Hemsley | 596,154 | 0 | 60,000,024 | 0 | 60,938,062 |
| 4 | Cisco Systems | 2025 | Charles Robbins | 1,390,000 | 45,870,690 | 0 | 5,117,424 | 52,838,751 |
| 5 | Salesforce.com | 2026 | Marc Benioff | 1,550,000 | 27,265,360 | 10,743,097 | 3,602,588 | 49,379,252 |
| 6 | Walt Disney | 2025 | Robert Iger | 1,000,000 | 21,000,057 | 14,000,006 | 7,250,000 | 45,842,574 |
| 7 | IBM | 2025 | Arvind Krishna | 1,500,000 | 23,988,586 | 6,606,312 | 5,250,000 | 37,989,685 |
| 8 | Eli Lilly | 2025 | David Ricks | 1,700,000 | 23,325,000 | 0 | 6,485,500 | 36,698,337 |
| 9 | Nvidia | 2026 | Jen-Hsun Huang | 1,497,627 | 24,800,511 | 0 | 6,000,000 | 36,343,830 |
| 10 | Nike | 2026 | Elliott Hill | 1,500,000 | 28,137,798 | 3,967,113 | 2,220,000 | 36,340,876 |
| 11 | Verizon | 2025 | Daniel Schulman | 375,000 | 32,774,795 | 0 | 937,500 | 34,311,016 |
| 12 | Johnson & Johnson | 2025 | Joaquin Duato | 1,600,000 | 15,028,948 | 5,927,995 | 4,298,700 | 32,758,111 |
| 13 | Visa | 2025 | Ryan McInerney | 1,505,782 | 18,723,306 | 5,687,509 | 5,250,000 | 31,560,660 |
| 14 | Coca-Cola | 2025 | James Quincey | 1,675,000 | 12,516,109 | 10,352,255 | 5,025,000 | 31,208,165 |
| 15 | Gilead Sciences | 2025 | Daniel O'Day | 1,795,192 | 15,238,402 | 4,500,060 | 4,848,120 | 28,437,198 |
| 16 | Chevron | 2025 | Michael Wirth | 1,900,000 | 13,524,995 | 4,376,640 | 3,562,500 | 26,828,240 |
| 17 | Amgen | 2025 | Robert Bradway | 1,925,409 | 12,599,589 | 5,399,996 | 3,907,000 | 24,693,120 |
| 18 | Boeing | 2025 | Robert Ortberg | 1,500,000 | 7,874,818 | 9,624,959 | 3,930,000 | 23,581,389 |
| 19 | Procter & Gamble | 2025 | Jon Moeller | 1,637,500 | 11,519,645 | 6,562,515 | 0 | 21,909,816 |
| 20 | Bristol-Myers Squibb | 2025 | Christopher Boerner | 1,586,346 | 16,061,399 | 0 | 3,754,684 | 21,879,919 |
| 21 | 3M | 2025 | William Brown | 1,800,000 | 7,753,852 | 7,001,242 | 3,745,322 | 21,005,009 |
| 22 | Merck & Co., Inc. | 2025 | Robert Davis | 1,645,302 | 12,102,838 | 3,380,004 | 2,326,500 | 20,797,845 |
| 23 | McDonald's | 2025 | Christopher Kempczinski | 1,550,000 | 8,000,215 | 8,000,066 | 2,367,160 | 20,574,525 |
| 24 | Honeywell | 2025 | Vimal Kapur | 1,600,000 | 10,866,269 | 3,623,914 | 3,516,800 | 20,381,435 |
| 25 | Caterpillar | 2025 | Joseph Creed | 1,381,892 | 9,538,484 | 3,101,117 | 2,476,800 | 17,008,077 |
| 26 | Home Depot | 2025 | Edward Decker | 1,400,000 | 9,612,251 | 2,369,917 | 2,657,631 | 16,191,127 |
| 27 | Sherwin-Williams | 2025 | Heidi Petz | 1,373,077 | 6,456,207 | 4,253,859 | 2,390,000 | 14,914,317 |
| 28 | Amazon | 2025 | Andrew Jassy | 365,000 | 0 | 0 | 0 | 2,069,861 |
| — | Novartis | — | — | — | — | — | — | not in coverage universe |
| — | Sanofi | — | — | — | — | — | — | not in coverage universe |
| — | AstraZeneca | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Merck & Co., Inc. | 94% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (R-TSR) | FW Cook |
| 3M | 118.9% | PSU 50 · Options 50 | No | FW Cook |
| Amazon | not disclosed | RSU 100 | not disclosed | None (Committee may engage compensation consultants but did not do so in 2025) |
| Amgen | 136.0% | PSU 50 · Options 30 · RSU 20 | Yes — relative TSR | Frederic W. Cook & Co., Inc. (FW Cook) |
| Apple | not disclosed | not disclosed | not disclosed | Pay Governance LLC |
| AstraZeneca | not disclosed | not disclosed | not disclosed | not disclosed |
| Boeing | 131% | Options 55 · RSU 45 | not disclosed | FW Cook (Frederic W. Cook & Co., Inc.) |
| Bristol-Myers Squibb | 157.66% | PSU 60 · MSU 40 | Yes — 3-Year Relative TSR CAGR | Farient Advisors LLC |
| Caterpillar | 118% | PSU 50 · RSU 25 · Options 25 | Yes — relative Total Shareholder Return (rTSR) | Meridian Compensation Partners, LLC |
| Chevron | 125% | PSU 50 · RSU 25 · Options 25 | Yes — Relative Total Stockholder Return (TSR) | Meridian Compensation Partners, LLC |
| Cisco Systems | 142% | PSU 60 · RSU 40 | Yes — Relative TSR | Exequity |
| Coca-Cola | 150% | PSU 50 · Options 50 | Yes — Relative TSR modifier | Meridian Compensation Partners, LLC |
| Eli Lilly | 218% | PSU 100 | No | FW Cook |
| Gilead Sciences | 180% | PSU 50 · Options 25 · RSU 25 | Yes — Relative TSR | FW Cook |
| Home Depot | 95% | PSU 50 · RSU 30 · Options 20 | No | Pay Governance |
| Honeywell | 126% | PSU 50 · Options 25 · RSU 25 | Yes — three-year total shareowner return (TSR) relative to the 2025 Compensation Peer Group | not disclosed |
| IBM | 150% | not disclosed | Yes — Relative Total Shareholder Return (rTSR) | Semler Brossy |
| Johnson & Johnson | not disclosed | not disclosed | not disclosed | Semler Brossy Consulting Group |
| McDonald's | not disclosed | PRSU 50 · Option 50 | not disclosed | Semler Brossy Consulting Group LLC |
| Microsoft | not disclosed | PSA 100 | not disclosed | Pay Governance LLC |
| Nike | 74% | PSU 50 · Options 25 · RSU 25 | Yes — Relative TSR | None retained in fiscal 2026 (market data supplemented via Aon, Willis Towers Watson, and Mercer) |
| Novartis | not disclosed | not disclosed | not disclosed | not disclosed |
| Nvidia | 200% | PSU 100 | Yes — TSR relative to the S&P 500 | Semler Brossy |
| Procter & Gamble | 57% | PSU 50 | Yes — Relative TSR Multiplier | Meridian Compensation Partners, LLC |
| Salesforce.com | 103.3% | PSU 67 · Options 33 | Yes — Relative TSR | Semler Brossy |
| Sanofi | not disclosed | not disclosed | not disclosed | not disclosed |
| Sherwin-Williams | 110.86% | PSU 60 · Options 40 | No | Mercer (US) LLC |
| UnitedHealth Group | not disclosed | PSU 50 · Options 25 · RSU 25 | No | Pay Governance |
| Verizon | 100% | PSU 60 · RSU 40 | Yes — relative total shareholder return (TSR) position compared with the companies in the S&P 100 | Meridian Compensation Partners, LLC |
| Visa | 140% | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR vs. S&P 500 | Meridian |
| Walt Disney | 144.4% | PSU 60 · Options 40 | Yes — TSR performance relative to the S&P 500 Media & Entertainment Index | Pay Governance LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Robert Davis | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Summary Compensation Table” · page 62. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022 |
| 2 | Section 01, Dean Li | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Summary Compensation Table” · page 62. As printed: 8,892,881. Filing ↗machine: r11 · c35 · span 1428543–1428552 |
| 3 | Section 01, Caroline Litchfield | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Summary Compensation Table” · page 62. As printed: 7,514,085. Filing ↗machine: r5 · c35 · span 1390128–1390137 |
| 4 | Section 01, Jennifer Zachary | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Summary Compensation Table” · page 62. As printed: 5,860,578. Filing ↗machine: r14 · c35 · span 1447636–1447645 |
| 5 | Section 01, Sanat Chattopadhyay | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Summary Compensation Table” · page 62. As printed: 5,408,408. Filing ↗machine: r8 · c35 · span 1409249–1409258 |
| 6 | Section 03, Dean Li OPTION | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t253 · r9 · c7 · span 1341027–1341033 |
| 7 | Section 03, Robert Davis PSU | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t310 · r4 · c51 · span 1812555–1812564 |
| 8 | Section 03, Caroline Litchfield OPTION | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t253 · r5 · c7 · span 1333710–1333716 |
| 9 | Section 03, Dean Li PSU | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t310 · r28 · c51 · span 1899295–1899304 |
| 10 | Section 03, Caroline Litchfield RSU | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t310 · r14 · c51 · span 1848680–1848689 |
| 11 | Section 03, Caroline Litchfield PSU | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t310 · r12 · c51 · span 1841449–1841458 |
| 12 | Section 03, Robert Davis RSU | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t310 · r6 · c51 · span 1819786–1819795 |
| 13 | Section 03, Dean Li RSU | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t310 · r30 · c51 · span 1906526–1906535 |
| 14 | Section 03, Robert Davis OPTION | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t253 · r3 · c7 · span 1330053–1330060 |
| 15 | Section 03, Jennifer Zachary RSU | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t310 · r38 · c51 · span 1935423–1935430 |
| 16 | Section 03, Sanat Chattopadhyay PSU | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t310 · r20 · c51 · span 1870409–1870418 |
| 17 | Section 03, Jennifer Zachary PSU | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t310 · r36 · c51 · span 1928193–1928202 |
| 18 | Section 03, Jennifer Zachary OPTION | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t253 · r11 · c7 · span 1344666–1344672 |
| 19 | Section 03, Sanat Chattopadhyay RSU | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t310 · r22 · c51 · span 1877639–1877646 |
| 20 | Section 03, Sanat Chattopadhyay OPTION | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t253 · r7 · c7 · span 1337383–1337389 |
| 21 | Section 07, pay ratio | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “CEO Pay Ratio”. As printed: 191 : 1. Filing ↗machine: span 1584866–1584874 |
| 22 | Section 08, Thomas H. Glocer | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 415,000. Filing ↗machine: t176 · r10 · c11 · span 973126–973133 |
| 23 | Section 08, Pamela J. Craig | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 405,000. Filing ↗machine: t176 · r8 · c11 · span 971271–971278 |
| 24 | Section 08, Surendralal L. Karsanbhai | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 405,000. Filing ↗machine: t176 · r12 · c11 · span 975046–975053 |
| 25 | Section 08, Paul B. Rothman, M.D | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 405,000. Filing ↗machine: t176 · r18 · c11 · span 980674–980681 |
| 26 | Section 08, Christine E. Seidman, M.D | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 385,000. Filing ↗machine: t176 · r22 · c11 · span 984395–984402 |
| 27 | Section 08, Patricia F. Russo | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 365,000. Filing ↗machine: t176 · r20 · c11 · span 982530–982537 |
| 28 | Section 08, Douglas M. Baker Jr | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 350,000. Filing ↗machine: t176 · r4 · c11 · span 967564–967572 |
| 29 | Section 08, Stephen L. Mayo, Ph.D | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 350,000. Filing ↗machine: t176 · r16 · c11 · span 978814–978821 |
| 30 | Section 08, Risa J. Lavizzo-Mourey, M.D | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 340,000. Filing ↗machine: t176 · r14 · c11 · span 976953–976960 |
| 31 | Section 08, Kathy J. Warden | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 340,000. Filing ↗machine: t176 · r26 · c11 · span 988099–988106 |
| 32 | Section 08, Inge G. Thulin | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 340,000. Filing ↗machine: t176 · r24 · c11 · span 986248–986255 |
| 33 | Section 08, Mary Ellen Coe | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 340,000. Filing ↗machine: t176 · r6 · c11 · span 969417–969424 |
| 34 | Section 08, Robert M. Davis | DEF 14A | 2026-04-08 | 0001193125-26-147704 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 35 | Section 02, Dalton E. Smart III 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Dalton E. Smart III 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Dalton E. Smart III 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Jennifer Zachary 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Betty D. Larson 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Betty D. Larson 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Betty D. Larson 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Dean Li 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Dean Li 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Dean Li 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Robert M. Davis 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000080 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, David Michael Williams 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Jennifer Zachary 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Chirfi Guindo 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Sanat Chattopadhyay 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Sanat Chattopadhyay 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, David Michael Williams 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, David Michael Williams 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Dalton E. Smart III 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Jennifer Zachary 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Betty D. Larson 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Caroline Litchfield 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Robert M. Davis 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000080 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Johannes Jacobus Oosthuizen 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Johannes Jacobus Oosthuizen 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Betty D. Larson 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Caroline Litchfield 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Johannes Jacobus Oosthuizen 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Chirfi Guindo 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Richard R. DeLuca 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000096 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Richard R. DeLuca 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000096 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Robert M. Davis 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000080 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Dalton E. Smart III 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Richard R. DeLuca 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000096 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Chirfi Guindo 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Betty D. Larson 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Caroline Litchfield 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Dalton E. Smart III 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Sanat Chattopadhyay 2026-04-29 | Form 4 | 2026-05-01 | 0000310158-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Dalton E. Smart III 2026-05-02 | Form 4 | 2026-05-05 | 0000310158-26-000115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, David R. Maraldo 2026-05-02 | Form 4 | 2026-05-05 | 0000310158-26-000113 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Dalton E. Smart III 2026-05-02 | Form 4 | 2026-05-05 | 0000310158-26-000115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Dalton E. Smart III 2026-05-02 | Form 4 | 2026-05-05 | 0000310158-26-000115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, David R. Maraldo 2026-05-02 | Form 4 | 2026-05-05 | 0000310158-26-000113 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, David R. Maraldo 2026-05-02 | Form 4 | 2026-05-05 | 0000310158-26-000113 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Chirfi Guindo 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Chirfi Guindo 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Jennifer Zachary 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, David R. Maraldo 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000123 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Johannes Jacobus Oosthuizen 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Dean Li 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000133 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Betty D. Larson 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Robert M. Davis 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000127 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Dalton E. Smart III 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Jennifer Zachary 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, David Michael Williams 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000137 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Caroline Litchfield 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000135 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Caroline Litchfield 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000135 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Dean Li 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000133 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Betty D. Larson 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Richard R. DeLuca 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Richard R. DeLuca 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Robert M. Davis 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000127 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Brian Foard 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Brian Foard 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Brian Foard 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, David R. Maraldo 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000123 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Johannes Jacobus Oosthuizen 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Dalton E. Smart III 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, David Michael Williams 2026-05-05 | Form 4 | 2026-05-07 | 0000310158-26-000137 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Douglas M. Baker Jr 2026-05-29 | Form 4 | 2026-06-02 | 0000310158-26-000146 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Thomas H. Glocer 2026-05-29 | Form 4 | 2026-06-02 | 0000310158-26-000150 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Paul Rothman 2026-05-29 | Form 4 | 2026-06-02 | 0000310158-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Christine E. Seidman 2026-05-29 | Form 4 | 2026-06-02 | 0000310158-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Surendralal L. Karsanbhai 2026-05-29 | Form 4 | 2026-06-02 | 0000310158-26-000171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Stephen Mayo 2026-05-29 | Form 4 | 2026-06-02 | 0000310158-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Patricia F. Russo 2026-05-29 | Form 4 | 2026-06-02 | 0000310158-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Pamela J. Craig 2026-05-29 | Form 4 | 2026-06-02 | 0000310158-26-000148 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Inge G. Thulin 2026-05-29 | Form 4 | 2026-06-02 | 0000310158-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Kathy J. Warden 2026-05-29 | Form 4 | 2026-06-02 | 0000310158-26-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Mary Ellen Coe 2026-05-29 | Form 4 | 2026-06-02 | 0000310158-26-000166 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Risa J. Lavizzo-Mourey 2026-05-29 | Form 4 | 2026-06-02 | 0000310158-26-000153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Mary Ellen Coe 2026-06-30 | Form 4 | 2026-07-01 | 0000310158-26-000198 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Christine E. Seidman 2026-06-30 | Form 4 | 2026-07-01 | 0000310158-26-000202 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Surendralal L. Karsanbhai 2026-06-30 | Form 4 | 2026-07-01 | 0000310158-26-000200 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 06, 2026 vote | Form 8-K | 2026-05-28 | 0001104659-26-067509 | Item 5.07 · say-on-pay result. As reported: 94.06% (votes for as printed: 1,730,192,132). Filing ↗ |
| 121 | Section 06, 2025 vote | Form 8-K | 2025-05-29 | 0001104659-25-054131 | Item 5.07 · say-on-pay result. As reported: 91.46% (votes for as printed: 1,673,231,538). Filing ↗ |
| 122 | Section 06, 2024 vote | Form 8-K | 2024-05-30 | 0001628280-24-025800 | Item 5.07 · say-on-pay result. As reported: 93.5% (votes for as printed: 1,696,772,487). Filing ↗ |
| 123 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 124 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 125 | Section 09b board cost (computed) | Computed | — | computed | Cash 1,650,000 + equity 220,000 + all other 2,570,000 = 4,440,000, summed across the director compensation table rows.machine: formula: Σ = 4,440,000 |
| 126 | Microsoft, Section 10b CEO total | DEF 14A | 2025-10-21 | 0001193125-25-245150 | CEO total compensation as printed in Microsoft's own proxy. As printed: 96,496,790. Filing ↗machine: r2 · c27 · span 1059364–1059374 |
| 127 | Apple, Section 10b CEO total | DEF 14A | 2026-01-08 | 0001308179-26-000008 | CEO total compensation as printed in Apple's own proxy. As printed: 74,294,811. Filing ↗machine: span 549351–549361 |
| 128 | UnitedHealth Group, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001104659-26-046125 | CEO total compensation as printed in UnitedHealth Group's own proxy. As printed: 60,938,062. Filing ↗machine: r1 · c48 · span 1832651–1832661 |
| 129 | Cisco Systems, Section 10b CEO total | DEF 14A | 2025-10-28 | 0000858877-25-000150 | CEO total compensation as printed in Cisco Systems's own proxy. As printed: 52,838,751. Filing ↗machine: r2 · c33 · span 1073719–1073729 |
| 130 | Salesforce.com, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001108524-26-000085 | CEO total compensation as printed in Salesforce.com's own proxy. As printed: 49,379,252. Filing ↗machine: r4 · c24 · span 1710833–1710843 |
| 131 | Walt Disney, Section 10b CEO total | DEF 14A | 2026-01-22 | 0001744489-26-000013 | CEO total compensation as printed in Walt Disney's own proxy. As printed: 45,842,574. Filing ↗machine: r3 · c27 · span 1324221–1324231 |
| 132 | IBM, Section 10b CEO total | DEF 14A | 2026-03-10 | 0000051143-26-000025 | CEO total compensation as printed in IBM's own proxy. As printed: 37,989,685. Filing ↗machine: r11 · c51 · span 1119293–1119303 |
| 133 | Eli Lilly, Section 10b CEO total | DEF 14A | 2026-03-20 | 0000059478-26-000029 | CEO total compensation as printed in Eli Lilly's own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024 |
| 134 | Nvidia, Section 10b CEO total | DEF 14A | 2026-05-12 | 0001045810-26-000036 | CEO total compensation as printed in Nvidia's own proxy. As printed: 36,343,830. Filing ↗machine: span 967967–967977 |
| 135 | Nike, Section 10b CEO total | DEF 14A | 2026-07-15 | 0000320187-26-000089 | CEO total compensation as printed in Nike's own proxy. As printed: 36,340,876. Filing ↗machine: t55 · r2 · c10 · span 647557–647567 |
| 136 | Verizon, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001308179-26-000210 | CEO total compensation as printed in Verizon's own proxy. As printed: 34,311,016. Filing ↗machine: t26 · r1 · c16 · span 239072–239082 |
| 137 | Johnson & Johnson, Section 10b CEO total | DEF 14A | 2026-03-11 | 0000200406-26-000063 | CEO total compensation as printed in Johnson & Johnson's own proxy. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246 |
| 138 | Visa, Section 10b CEO total | DEF 14A | 2025-12-08 | 0001308179-25-000635 | CEO total compensation as printed in Visa's own proxy. As printed: 31,560,660. Filing ↗machine: t249 · span 1369402–1369412 |
| 139 | Coca-Cola, Section 10b CEO total | DEF 14A | 2026-03-16 | 0001104659-26-028215 | CEO total compensation as printed in Coca-Cola's own proxy. As printed: 31,208,165. Filing ↗machine: t286 · r11 · c26 · span 3291227–3291237 |
| 140 | Gilead Sciences, Section 10b CEO total | DEF 14A | 2026-03-20 | 0001308179-26-000106 | CEO total compensation as printed in Gilead Sciences's own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592 |
| 141 | Chevron, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145617 | CEO total compensation as printed in Chevron's own proxy. As printed: 26,828,240. Filing ↗machine: span 1241206–1241216 |
| 142 | Amgen, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145588 | CEO total compensation as printed in Amgen's own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166 |
| 143 | Boeing, Section 10b CEO total | DEF 14A | 2026-03-06 | 0001193125-26-096787 | CEO total compensation as printed in Boeing's own proxy. As printed: 23,581,389. Filing ↗machine: r2 · c44 · span 1170571–1170581 |
| 144 | Procter & Gamble, Section 10b CEO total | DEF 14A | 2025-08-29 | 0001193125-25-191749 | CEO total compensation as printed in Procter & Gamble's own proxy. As printed: 21,909,816. Filing ↗machine: t160 · r6 · c44 · span 892224–892234 |
| 145 | Bristol-Myers Squibb, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000014272-26-000006 | CEO total compensation as printed in Bristol-Myers Squibb's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170 |
| 146 | 3M, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000066740-26-000151 | CEO total compensation as printed in 3M's own proxy. As printed: 21,005,009. Filing ↗machine: r2 · c9 · span 2797692–2797702 |
| 147 | Merck & Co., Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-08 | 0001193125-26-147704 | CEO total compensation as printed in Merck & Co., Inc.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022 |
| 148 | McDonald's, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145548 | CEO total compensation as printed in McDonald's's own proxy. As printed: 20,574,525. Filing ↗machine: r4 · c25 · span 2683025–2683035 |
| 149 | Honeywell, Section 10b CEO total | DEF 14A | 2026-04-10 | 0000773840-26-000029 | CEO total compensation as printed in Honeywell's own proxy. As printed: 20,381,435. Filing ↗machine: span 2093429–2093439 |
| 150 | Caterpillar, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001308179-26-000358 | CEO total compensation as printed in Caterpillar's own proxy. As printed: 17,008,077. Filing ↗machine: span 855862–855872 |
| 151 | Home Depot, Section 10b CEO total | DEF 14A | 2026-04-07 | 0000354950-26-000090 | CEO total compensation as printed in Home Depot's own proxy. As printed: 16,191,127. Filing ↗machine: t169 · r4 · c15 · span 1200990–1201000 |
| 152 | Sherwin-Williams, Section 10b CEO total | DEF 14A | 2026-03-11 | 0000089800-26-000025 | CEO total compensation as printed in Sherwin-Williams's own proxy. As printed: 14,914,317. Filing ↗machine: r2 · c8 · span 1976552–1976562 |
| 153 | Amazon, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001104659-26-041026 | CEO total compensation as printed in Amazon's own proxy. As printed: 2,069,861. Filing ↗machine: span 1010745–1010754 |
| 154 | Section 10a, Bristol-Myers Squibb reciprocity | DEF 14A | — | 0000014272-26-000006 | Bristol-Myers Squibb names Merck & Co., Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 155 | Section 10a, Eli Lilly reciprocity | DEF 14A | — | 0000059478-26-000029 | Eli Lilly names Merck & Co., Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 156 | Section 10a, Chevron reciprocity | DEF 14A | — | 0001193125-26-145617 | Chevron names Merck & Co., Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 157 | Section 10a, Nike reciprocity | DEF 14A | — | 0000320187-26-000089 | Nike's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 158 | Section 10a, Caterpillar reciprocity | DEF 14A | — | 0001308179-26-000358 | Caterpillar's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 159 | Section 10a, UnitedHealth Group reciprocity | DEF 14A | — | 0001104659-26-046125 | UnitedHealth Group's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 160 | Section 10a, Gilead Sciences reciprocity | DEF 14A | — | 0001308179-26-000106 | Gilead Sciences names Merck & Co., Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 161 | Section 10a, Johnson & Johnson reciprocity | DEF 14A | — | 0000200406-26-000063 | Johnson & Johnson names Merck & Co., Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 162 | Section 10a, Amgen reciprocity | DEF 14A | — | 0001193125-26-145588 | Amgen names Merck & Co., Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 163 | Section 10a, IBM reciprocity | DEF 14A | — | 0000051143-26-000025 | IBM's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 164 | Section 10a, Honeywell reciprocity | DEF 14A | — | 0000773840-26-000029 | Honeywell's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 165 | Section 10a, Amazon reciprocity | DEF 14A | — | 0001104659-26-041026 | Amazon's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 166 | Section 10a, Apple reciprocity | DEF 14A | — | 0001308179-26-000008 | Apple's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 167 | Section 10a, Visa reciprocity | DEF 14A | — | 0001308179-25-000635 | Visa's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 168 | Section 10a, Boeing reciprocity | DEF 14A | — | 0001193125-26-096787 | Boeing's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 169 | Section 10a, Microsoft reciprocity | DEF 14A | — | 0001193125-25-245150 | Microsoft names Merck & Co., Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 170 | Section 10a, Nvidia reciprocity | DEF 14A | — | 0001045810-26-000036 | Nvidia's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 171 | Section 10a, Salesforce.com reciprocity | DEF 14A | — | 0001108524-26-000085 | Salesforce.com's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 172 | Section 10a, Sherwin-Williams reciprocity | DEF 14A | — | 0000089800-26-000025 | Sherwin-Williams's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 173 | Section 10a, Verizon reciprocity | DEF 14A | — | 0001308179-26-000210 | Verizon names Merck & Co., Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 174 | Section 10a, 3M reciprocity | DEF 14A | — | 0000066740-26-000151 | 3M's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 175 | Section 10a, Walt Disney reciprocity | DEF 14A | — | 0001744489-26-000013 | Walt Disney's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 176 | Section 10a, Procter & Gamble reciprocity | DEF 14A | — | 0001193125-25-191749 | Procter & Gamble names Merck & Co., Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 177 | Section 10a, Coca-Cola reciprocity | DEF 14A | — | 0001104659-26-028215 | Coca-Cola's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 178 | Section 10a, Cisco Systems reciprocity | DEF 14A | — | 0000858877-25-000150 | Cisco Systems's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |
| 179 | Section 10a, Home Depot reciprocity | DEF 14A | — | 0000354950-26-000090 | Home Depot's most recent proxy was read; its disclosed peer group does not include Merck & Co., Inc.. Filing ↗ |